Careful use of science to advance the debate on the UK Cancer Drugs Fund

JAMA. 2014 Jan 1;311(1):25-6. doi: 10.1001/jama.2013.282839.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents / economics*
  • Cost-Benefit Analysis
  • Drug Industry / economics
  • Evidence-Based Medicine*
  • Financing, Government*
  • Health Policy
  • Humans
  • Insurance Coverage
  • Patient Preference
  • Randomized Controlled Trials as Topic
  • State Medicine / economics*
  • United Kingdom

Substances

  • Antineoplastic Agents